NCT06517784Completed
Insulin Initiation and Adherence Behaviours: a Cross Sectional Survey of Indian HCPs & Patients With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 28 Aug 2024
Brief summary (registry, in English)
This is a cross-sectional study planned among patients with Type 2 Diabetes (T2D) and Health Care Providers (HCPs) who treat T2D patients. Study participants will be recruited through existing databases/panels to complete a 30-minute self-administered online survey. The purpose of the study is to understand the insulinization barriers and the insulin adherence behaviours of both HCPs and patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 752 (actual)
- First submitted
- 18 Jul 2024
- Start date
- 5 Jul 2024
- Primary completion date
- 16 Aug 2024
- Lead sponsor
- Novo Nordisk A/S
- Diseases
- Type 2 diabetes
- NCT number
- NCT06517784
What you commit to
- Study type: Observational
- Participants enrolled: 752
- From 5 Jul 2024 to the primary completion date, 16 Aug 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous participation in this study. Participation is defined as having given informed consent in this study
Other
- Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Who the study is looking for
- For patients
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Diagnosed with T2D
- Currently seeing an HCP for T2D
- Initiated on insulin within the past 12 months
- Prescribed insulin on a permanent basis
- Currently taking insulin via a vial and syringe or insulin pen
- For HCP
- Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
- Male or female, age above or equal to 18 years at the time of signing informed consent.
- Primary care physician (PCP) with degree in internal medicine or general medicine, diabetologist with degree in internal medicine or general medicine plus diploma in diabetology, or endocrinologist
- Has been in practice a minimum of 2 years
- Diabetologist/endocrinologist: treats at least 50 T2D patients per month
- PCP: treats at least 40 T2D patients per month
- Currently initiates T2D patients on insulin
- Treats 20 percent or more of T2D patients with insulin
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novo Nordisk India Coordinator of this site? Confirm its status | Bangalore | India | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.